Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis

Oncotarget. 2017 Jul 11;8(28):46425-46435. doi: 10.18632/oncotarget.17436.

Abstract

Background: Soluble mesothelin is beneficial to detect the progression and the treatment response of malignant pleural mesothelioma. However, the prognostic value of soluble mesothelin in malignant pleural mesothelioma remains unclear.

Methods: Hazard ratio with 95% CI was used to evaluate the prognostic value of soluble mesothelin and the effect of clinicopathological characteristics on the survival of malignant pleural mesothelioma.

Results: Eight eligible studies involving 579 patients were selected for this meta-analysis. The results showed that soluble mesothelin level was significantly correlated with the survival of malignant pleural mesothelioma (pooled HR: 1.958, 95%CI: 1.531-2.504, p = 0.000; heterogeneity test: I2 = 1.1%, p = 0.421). In addition, the survival of malignant pleural mesothelioma was significantly correlated with some clinicopathological characteristics such as tumor histology (HR = 3.214, 95% CI = 2.071-4.988, p = 0.000; heterogeneity test: I2 = 0.0%, p = 0.623) and tumor stage (HR = 2.007; 95% CI = 1.477-2.727; p = 0.000; heterogeneity test: I2 = 0.0%, p = 0.966).

Conclusions: The survival of malignant pleural mesothelioma is significantly correlated with tumor histology and tumor stage. Furthermore, high soluble mesothelin level may lead to a poor prognosis for malignant pleural mesothelioma patients.

Keywords: malignant pleural mesothelioma; meta-analysis; prognosis; soluble mesothelin.

Publication types

  • Meta-Analysis

MeSH terms

  • Biomarkers, Tumor*
  • Female
  • GPI-Linked Proteins / metabolism*
  • Humans
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / mortality*
  • Lung Neoplasms / pathology
  • Male
  • Mesothelin
  • Mesothelioma / metabolism*
  • Mesothelioma / mortality*
  • Mesothelioma / pathology
  • Mesothelioma, Malignant
  • Neoplasm Grading
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Pleural Neoplasms / metabolism*
  • Pleural Neoplasms / mortality*
  • Pleural Neoplasms / pathology
  • Prognosis
  • Proportional Hazards Models
  • Publication Bias

Substances

  • Biomarkers, Tumor
  • GPI-Linked Proteins
  • Mesothelin